Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Fig. 3

Kaplan-Meier curves for progression-free survival. The median progression-free survival was 9.2 months (95% confidence interval [CI], 8.3–10.7) for CPB and 7.9 months (95% CI 6.1–8.6) for CPA (HR 0.62, 95%CI, 0.47–0.82; p < 0.001). *The hazard ratio was calculated using a Cox proportional hazards model, with the age, BMI, haemoglobin < 11 g/dL, histology, IVB CC, duration of drug, performance scores, and number of metastatic sites used as covariates and therapy as the time-dependent factor

Back to article page
\